Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Sustained Release Excipients Market Evolve in Terms of Growth and Size by 2029?

In the past few years, the market size for sustained release excipients has seen substantial growth. The market is projected to expand from $1.4 billion in 2024 to $1.51 billion in 2025, with an 8.1% compound annual growth rate (CAGR). This upward trend in the historical period can be credited to factors such as the rising demand for controlled drug release, the prevalent cases of chronic diseases, patient compliance and convenience, innovative strides in the pharmaceutical industry, and regulatory backing for extended-release formulations.

The market size of sustained release excipients is projected to significantly expand in the coming years, with an estimation of reaching $2.1 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.5%. The driving forces behind this anticipated growth during the forecast period may be the growing elderly population, increased attention towards personalized medication, patient adherence challenges, the rise of complex drug formulations, advancements in disease management, and the expansion of global healthcare. Key trends predicted within this time frame include a focus on patient-focused drug delivery, partnerships for formulation development, regulatory compliance and safety, worldwide extension of drug formulation technologies, and the impact of biopharmaceuticals.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

What factors are expected to fuel Sustained Release Excipients market growth in the coming years?

The sustained-release excipients market growth is anticipated to surge owing to the escalating prevalence of chronic and acute diseases. Chronic ailments, which last for an extended time, typically more than three months, and acute illnesses, characterized by rapid and usually severe but short-lived symptoms, are two categories that illnesses are classified into. The formulations of pharmaceutical products for both types of diseases extensively involve the use of sustained-release excipients. It enhances patient compliance, ensures uniform drug levels, minimizes side effects, and streamlines disease management, factors that augment the sales of sustained-release excipients. As reported by the World Health Organization (WHO), a health agency based in Switzerland, in September 2022, the most deaths from non-communicable diseases were due to cardiovascular diseases, amounting to 17.9 million people annually. This was followed by chronic respiratory diseases (4.1 million), diabetes (2.0 million, inclusive of deaths from kidney disease caused by diabetes), and cancer (9.3 million). An August 2022 report published by the American College of Cardiology, a non-profit medical association based in the US, projected significant rises from 2025 to 2060 in all four major cardiovascular risk factors in the US. It anticipates diabetes witnessing the highest proportional rise, soaring by 39.3% to 55 million individuals. This will be closely followed by dyslipidemia (increasing by 27.6% to 126 million), hypertension (rising by 25.1% to 162 million), and obesity (escalating by 18.3% to 126 million). Moreover, considerable rises are predicted in stroke rates (33.8% to 15 million) and heart failure (33.4% to 13 million), with ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) right on their heels. Therefore, the burgeoning prevalence of chronic and acute diseases is projected to drive the growth of the sustained-release excipients market.

What Are The Key Findings From The Segmentation Analysis Of The Sustained Release Excipients Market?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars

5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols

6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Which Trends Are Expected To Shape The Future Of The Sustained Release Excipients Market?

Innovations in product development are becoming a significant trend in the scar treatment market. Key market players are evolving skincare technology with the intention to boost treatment effectiveness, better patient outcomes, and offer non-invasive alternatives for those desiring scar diminution. The objective of this technology is to augment the efficiency of treatments, increase safety measures, and deliver ideal results for a range of skin worries. For example, Doctors Aesthetics Centre, a company based in India, introduced Picocare Majesty, an innovative laser skincare gadget, for the first time in South India in March 2023. This tool employs the latest picosecond technology to specifically address and manage diverse scar issues, encompassing acne scars, surgical scars, and pigmentation problems.

What Are The Most Active Companies In The Sustained Release Excipients Market Today?

Major companies operating in the sustained release excipients market include BASF SE, Ashland Global Holdings Inc., Colorcon Inc., Croda International Plc, Dow Chemical Company, DuPont de Nemours Inc., Roquette Frères, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, JRS Pharma GmbH & Co. KG, Shin-Etsu Chemical Co.Ltd., Gattefossé SAS, Eastman Chemical Company, Cellulose Solutions Private Limited, Avantor Inc., SPI Pharma Inc., Asahi Kasei Corporation, Chemische Fabrik Budenheim KG, Associated British Foods plc, Ransom Naturals Ltd, Balchem Corporation, IMCD Group, Lonza Group AG

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

Which Regional Markets Are Attracting The Most Investment In Sustained Release Excipients?

North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10822&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model